Milvexian didn’t scale back main adversarial cardiovascular occasions in contrast with placebo after a latest acute coronary syndrome and there was no enhance in intracranial or deadly bleeding. These have been the principle findings from the LIBREXIA ACS trial offered in a Scorching Line session as we speak at ESC Congress 2026 and printed concurrently within the New England Journal of Drugs. The outcomes observe a call to discontinue the trial in November 2025 as a result of futility at a preplanned interim evaluation.
Acute coronary syndrome (ACS), one of the complicated and difficult settings in cardiovascular care, describes a situation by which the guts’s blood provide is all of the sudden decreased, resembling throughout a myocardial infarction (MI). The danger of one other cardiovascular occasion stays excessive through the yr after ACS, even with using normal therapies together with twin antiplatelet therapies, statins and stents.
Including present anticoagulants to plain remedy has been examined to cut back recurrent thrombotic occasions, however bleeding threat was elevated. There was rising curiosity in growing issue XIa inhibitors to stop dangerous thrombosis, whereas preserving regular clotting processes to reduce bleeding. We carried out the LIBREXIA ACS trial to evaluate the efficacy and security of the selective issue XIa inhibitor, milvexian, after ACS when added to plain antiplatelet remedy.”
Professor P. Gabriel Steg, Principal Investigator of the LIBREXIA ACS trial, Hôpital Bichat, Paris, France
Eligible individuals had had an ACS inside seven days and had undergone cardiac catheterisation with percutaneous coronary intervention or have been being managed conservatively. Moreover, individuals needed to have at the least two elements related to elevated threat of recurrent ischemic occasions. All sufferers obtained normal antiplatelet remedy as decided by the investigator. A complete of 14,194 individuals at 893 websites in 44 nations have been randomized to oral milvexian 25 mg twice each day or a matched placebo.
The Unbiased Information Monitoring Committee really useful discontinuing the trial after a preplanned interim evaluation confirmed that it was unlikely to satisfy its major endpoint. Futility was confirmed when the info have been subsequently analyzed. After a median follow-up of 10 months, the first efficacy endpoint of cardiovascular loss of life, MI or ischemic stroke occurred at the same incidence in each teams: 5.4% of sufferers with milvexian and 5.1% of sufferers with placebo (hazard ratio [HR] 1.05; 95% confidence interval [CI] 0.91 to 1.21; p=0.50).
No distinction was noticed with milvexian for the person elements of the first endpoint or any main secondary efficacy endpoints, together with all-cause mortality.
The researchers discovered no distinction within the principal security endpoint of Bleeding Tutorial Analysis Consortium (BARC) 3c or 5 bleeding (intracranial or deadly bleeding), which occurred in 0.3% of sufferers with milvexian and placebo (HR 1.04; 95% CI 0.58 to 1.87; p=0.88).
Sufferers within the milvexian group had a protracted activated partial thromboplastin time suggesting that the dose of milvexian had the anticipated anticoagulant exercise.
Discussing the implications of those findings, Professor Steg mentioned: “Whereas no impact on efficacy was proven, the absence of an noticed enhance in intracranial or deadly bleeding is reassuring on condition that two additional trials are ongoing: LIBREXIA AF for sufferers with atrial fibrillation and LIBREXIA Stroke for secondary stroke prevention. These research are distinct from LIBREXIA ACS in a number of features, together with affected person populations, endpoints, sort and period of background remedy and illness pathology.”
Supply:
